Figure 2: T cell stimulatory capacity and morphology of CD40L-matured PDCs. Figure 3: Viability of DC subsets after stimulation with influenza and intracellular MxA expression. Figure 4 ...

However, most solid tumors, such as triple negative breast cancer (TNBC), do not have identifiable surface markers to distinguish themselves from normal cells, thus it is challenging to selectively ...

脑声小店基于深度科研洞察，专注为动物实验提供"简器械·精实验"解决方案。我们突破高精设备局限，开发手工定制化仪器及配件，通过科研巧思将基础工具转化为创新实验方案。产品涵盖行为学装置、操作辅助工具等，使实验室在保持操作简效的同时，实现精细化数据采集，助 ...

T regulatory cells, dendritic cells, macrophages, natural killer cells and neutrophils which are being developed as alternative immune cell therapies. NExT makes gene delivery quicker and less ...

T regulatory cells, dendritic cells, macrophages, natural killer cells and neutrophils which are being developed as alternative immune cell therapies. NExT makes gene delivery quicker and less ...

Then they used CAR T cell therapy to train the body's immune system to look for that synthetic antigen and destroy the marked tumor cells. "Tumor cells are sneaky. Most of the time, immune cells ...

Dubodencel, also known as DOC1021, is a first-in-class, double-loaded autologous dendritic cell therapy that uniquely combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is ...

A paradigm shift in the way we treat spinal injuries is now in sight, with the world's first regenerative cell therapy being granted approval for a registrational Phase I clinical trial.

CHICAGO, June 1 (Reuters) - A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal ...